Literature DB >> 18697876

Reassessment of sst2 somatostatin receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-1.

Thomas Fischer1, Christian Doll, Stefan Jacobs, Angela Kolodziej, Ralf Stumm, Stefan Schulz.   

Abstract

OBJECTIVE: The overexpression of somatostatin receptor 2 (sst2) in neuroendocrine tumors is the molecular basis for diagnostic and therapeutic application of the stable somatostatin analog octreotide. Recent evidence has shown that the immunocytochemical evaluation of sst2A status is of value for predicting response to octreotide therapy and disease prognosis. However, due to the lack of monoclonal and limited availability of specific polyclonal anti-sst2A antibodies, only very few patients can currently benefit from in vitro sst2 evaluation.
METHODS: In the present study, we extensively characterized the novel rabbit monoclonal anti-sst2A antibody (clone UMB-1) using tissues from sst2-deficient mice and their wild-type littermates. UMB-1 was then subjected to a comparative study of immunohistochemistry on a series of histological specimens from formalin-fixed, paraffin-embedded human tumors and adjacent normal tissues.
RESULTS: Immunoprecipitation experiments unequivocally demonstrated that UMB-1 selectively detected its cognate sst2A and did not cross-react with other proteins present in crude tissue homogenates. The UMB-1 monoclonal antibody, when compared with currently available polyclonal antisera, yielded several times more effective immunohistochemical staining of fixed-embedded tissues with a predominance of plasma membrane staining and very low cytoplasmic signal even without heat-based antigen retrieval. In addition, dual immunofluorescence revealed for the first time that the sst2A is present on not only gastrin-containing but also ghrelin-containing cells in human gastric mucosa.
CONCLUSION: Thus, the rabbit monoclonal antibody UMB-1 may prove of great value in the assessment of sst2A status in human neuroendocrine tumors during routine histopathological examination.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18697876     DOI: 10.1210/jc.2008-1063

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  53 in total

1.  Phosphorylation of sst2 receptors in neuroendocrine tumors after octreotide treatment of patients.

Authors:  Beatrice Waser; Renzo Cescato; Qisheng Liu; Yachu J Kao; Meike Körner; Emanuel Christ; Agnes Schonbrunn; Jean Claude Reubi
Journal:  Am J Pathol       Date:  2012-05       Impact factor: 4.307

Review 2.  Fine-tuning somatostatin receptor signalling by agonist-selective phosphorylation and dephosphorylation: IUPHAR Review 5.

Authors:  Stefan Schulz; Andreas Lehmann; Andrea Kliewer; Falko Nagel
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

3.  Differential regulation of somatostatin receptor dephosphorylation by β-arrestin1 and β-arrestin2.

Authors:  Andrea Kliewer; Stefan Schulz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-11-26       Impact factor: 3.000

4.  Molecular imaging with ⁶⁸Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours.

Authors:  Daniel Kaemmerer; Luisa Peter; Amelie Lupp; Stefan Schulz; Jörg Sänger; Vikas Prasad; Harshad Kulkarni; Sven-Petter Haugvik; Merten Hommann; Richard Paul Baum
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-05-31       Impact factor: 9.236

5.  Abdominal surgery inhibits circulating acyl ghrelin and ghrelin-O-acyltransferase levels in rats: role of the somatostatin receptor subtype 2.

Authors:  Andreas Stengel; Miriam Goebel-Stengel; Lixin Wang; Almaas Shaikh; Nils W G Lambrecht; Jean Rivier; Yvette Taché
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-06-02       Impact factor: 4.052

6.  Structural determinants of agonist-selective signaling at the sst(2A) somatostatin receptor.

Authors:  Falko Nagel; Christian Doll; Florian Pöll; Andrea Kliewer; Helmut Schröder; Stefan Schulz
Journal:  Mol Endocrinol       Date:  2011-02-17

7.  Rapid dephosphorylation of G protein-coupled receptors by protein phosphatase 1β is required for termination of β-arrestin-dependent signaling.

Authors:  Florian Pöll; Christian Doll; Stefan Schulz
Journal:  J Biol Chem       Date:  2011-07-27       Impact factor: 5.157

Review 8.  International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.

Authors:  Thomas Günther; Giovanni Tulipano; Pascal Dournaud; Corinne Bousquet; Zsolt Csaba; Hans-Jürgen Kreienkamp; Amelie Lupp; Márta Korbonits; Justo P Castaño; Hans-Jürgen Wester; Michael Culler; Shlomo Melmed; Stefan Schulz
Journal:  Pharmacol Rev       Date:  2018-10       Impact factor: 25.468

9.  Somatostatin and CXCR4 expression patterns in adenocarcinoma and squamous cell carcinoma of the lung relative to small cell lung cancer.

Authors:  Claudia Stumpf; Daniel Kaemmerer; Elisa Neubauer; Jörg Sänger; Stefan Schulz; Amelie Lupp
Journal:  J Cancer Res Clin Oncol       Date:  2018-08-03       Impact factor: 4.553

10.  Pasireotide and octreotide stimulate distinct patterns of sst2A somatostatin receptor phosphorylation.

Authors:  Florian Pöll; Diana Lehmann; Susann Illing; Mihaela Ginj; Stefan Jacobs; Amelie Lupp; Ralf Stumm; Stefan Schulz
Journal:  Mol Endocrinol       Date:  2010-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.